Osteoporosis is a major health problem worldwide and is projected to increase exponentially due to the aging of the population. Fractures, the most dreaded complication of bone disease are associated with high co-morbidity and mortality. The consequent public health and socioeconomic burden thus warrant timely diagnosis, treatment and follow-up of these disorders. Biochemical markers of bone turnover are convenient as the changes in their levels readily reflect bone physiology. Currently literature data advocate bone biomarkers as best used in monitoring anti-osteoporosis therapy efficacy and compliance, however there is abundant data supporting their role in predicting bone loss and fracture risk. Although dual energy x-ray absorptiometry (DEXA) is the gold standard to assess bone mass it does not account for fracture risk. Bone mineral density (BMD) measurement by DEXA has its own limitations being invasive, expensive and un- availability of machines at the primary level. Moreover changes in BMD measurements are static, reflecting at a particular site and observed after a year unlike changes in the bone turnover makers (BTMs) which occur within months of therapy. Due to these limitations, measurement of biomarkers from blood samples is an attractive alternative to evaluate bone turnover. The pre and post-analytic implications of bone turnover markers is mandatory in correct interpretation of test results. This mini review summarizes the most widely used BTMs, a look at more novel markers and discusses their strengths, weaknesses, feasibility of development of immunoassays, pre analytical issues and their clinical utility in the management of osteoporosis.
Keywords: Bone turnover markers, Hormones, Cytokines, Osteoporosis
Abbreviations: BMD: Bone Mineral Density; BSAP: Bone-Specific Alkaline Phosphatase; BTM: Bone Turnover Maker; Cr: Creatinine; CTX: C-Terminal Telopeptide of Type I Collagen; NTX: N-Terminal Telopeptide of Type I Collagen; DEXA: Dual Energy X-Ray Absorptiometry; DPD: Deoxypyridinoline; E1G: Estrone Glucuronide; ELISA: Enzyme Linked Immunosorbent Assay; FSH: Follicle Stimulating Hormone; HRT: Hormone Replacement Therapy; IL: Interleukin; OB: Osteoblast; OC: Osteoclast; OPG: Osteoprotegerin; OSC: Osteocalcin; PICP: C-Terminal Propeptide of Type I Collagen; PINP: N-terminal Propeptide of Type I Collagen; POF: Premature Ovarian Failure; PTH: Parathyroid Hormone; PyD: Pyridinoline; RANK: Receptor Activator of Nuclear Factor-Kappa B; RANKL: Receptor Activator of Nuclear Factor-Kappa B Ligand; TRAP: Tartrate-Resistant Acid Phosphatase
1. Kearns AE, Khosla S, Kostenuik PJ (2008) Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodelling in health and disease. Endocr Rev 29: 155-192.
2. Szulc P, Bauer DC, Eastell R (2013) Biochemical markers of bone turnover in osteoporosis. In: Rosen CJ, 8th edition. Primer on the metabolic bone diseases and disorders of mineral metabolism Washington DC, USA, pp: 297-306.
3. Hans D, Goertzen AL, Krieg MA, Leslie WD (2011) Bone microarchitecture assessed by TBS predicts osteoporotic fracturent independent of bone density: The Manitoba study. J Bone Miner Res 26: 2762-2769.
4. Burch J, Rice S, Yang H, Neilson A, Stirk L, et al. (2014) Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: The secondary prevention of fractures and primary prevention of fractures in high-risk groups. Health Technol Assess 18: 1-180.
5. Devogelaer JP, Boutsen Y, Gruson D, Manicourt D (2011) Is there a place for bone turnover markers in the assessment of osteoporosis and its treatment? Rheum Dis Clin North Am 37: 365-386.
6. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19: 385-397.
7. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, et al. (2006) The relative use of eight collagenous and non-collagenous markers for diagnosis of skeletal metastases in breast, prostate or lung cancer patients. Cancer Epidemiol Biomarkers Prev 15: 32-38.
8. Cremers S, Garnero P (2006) Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: Potential uses and pitfalls. Drugs 66: 2031-2058.
9. Costa AG, Bilezekian JP (2013) Bone turnover markers in primary hyperparathyroidism. J Clin Densitom 16: 22-27.
10. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, et al. (2010) Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142: 296-308.
11. Oury F, Sumara G, Sumara O, Ferron M, Chang H, et al. (2011) Endocrine regulation of male fertility by the skeleton. Cell 144: 796-809.
12. Oury F, Khrimian L, Denny CA, Gardin A, Chamouni A, et al. (2013) Maternal and offspring pools of osteocalcin influence brain development and functions. Cell 155: 228-241.
13. Rosenquist C, Qvist P, Bjarnason N, Christiansen C (1995) Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 41: 1439-1445.
14. Koivula MK, Ruotsalainen V, Björkman M, Nurmenniemi S, Ikäheimo R, et al. (2010) Difference between total and intact assays for N-terminal propeptide of type I procollagen reflects degradation of pN-collagen rather than denaturation of intact propeptide. Ann Clin Biochem 47: 67-71.
15. Woitge HW, Pecherstorfer M, Li Y, Keck AV, Horn E, et al. (1999) Novel serum markers of bone resorption: Clinical assessment and comparison with established urinary indices. J Bone Miner Res 14: 792-801.
16. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, et al. (1994) Direct enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9: 1643-1649.
17. Seibel MJ, Woitge H, Scheidt-Nave C, Leidig-Bruckner G, Duncan A, et al. (1994) Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: Results of a pilot study. J Bone Miner Res 9: 1433-1440.
18. Pagani F, Bonetti G, Stefini F, Panteghini M (2000) Evaluation of a fully automated assay to measure C-telopeptide of type I collagen in serum. Clin Chem Lab Med 38: 1111-1113.
19. Garnero P, Vergnaud P, Hoyle N (2008). Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 54: 188-196.
20. Wheater G, Elshahaly M, Tuck SP, Datta HK, van Laar JM (2013) The clinical utility of bone marker measurements in osteoporosis. J Transl Med 11: 201.
21. Sowers MR, Zheng H, Greendale GA, Neer RM, Cauley JA, et al. (2013) Changes in bone resorption across the menopause transition: Effects of reproductive hormones, body size and ethnicity. J Clin Endocrinol Metab 98: 2854-2863.
22. More C, Bhattoa HP, Bettembuk P, Balogh A (2003) The effects of pregnancy and lactation on hormonal status and biochemical markers of bone turnover. Eur J Obstet Gynecol Reprod Biol 106: 209-213.
23. Greenblatt MB, Tsai JN, Wein MN (2017) Bone turnover markers in the diagnosis and monitoring of metabolic bone disease. Clin Chem 63: 464-474.
24. Stokes FJ, Ivanov P, Bailey LM, Fraser WD (2011). The effect of sampling procedures and storage conditions on short-term stability of blood-based biochemical markers of bone metabolism. Clin Chem 57: 138-140.
25. Hannon R, Eastell R (2000) Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 11: 30-44.
26. Mozzanega B, Gizzo S, Bernardi D, Salmaso L, Patrelli TS, et al. (2013) Cyclic variations of bone resorption mediators and markers in the different phases of the menstrual cycle. J Bone Miner Metab 31: 461-467.
27. Gass ML, Kagan R, Kohles JD, Martens MG (2008) Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women. Menopause 15: 667-675.
28. Seibel MJ (2005) Biochemical markers of bone turnover. Part I: Biochemistry and Variability. Clin Biochem Rev 26: 97-122.
29. Hlaing TT, Compston JE (2014) Biochemical markers of bone turnover - Uses and limitations. Ann Clin Biochem 51: 189-202.
30. Desai MP, Khatkhatay MI, Bhanu Prakash KV, Savardekar LS, et al. (2007) Hormonal profiles and biochemical indices of bone turnover in Indian women. Osteoporos Int 18: 923-929.
31. Desai MP, Bhanuprakash KV, Khatkhatay MI, Donde UM (2007) Age related changes in bone turnover markers and ovarian hormones in pre- and post-menopausal Indian women. J Clinical Lab Anal 21: 55-60.
32. Chin KY (2018) The relationship between follicle stimulating hormone and bone health alternative explanation for bone loss beyond oestrogen. Int J Med Sci 15:1373-1383.
33. Delmas PD, Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34: 599-604.
34. Desai M, Khatkhatay MI, Taskar V, Ansari Z (2012) Changes in cytokines, biomarkers of bone turnover and hormones associated with bone loss in postmenopausal Indian women. Int J Endocrinol Metab 10: 399-403.
35. Uygur D, Sengül O, Bayar D, Erdinç S, Batioğlu S, et al. (2005) Bone loss in young women with premature ovarian failure. Arch Gynecol Obstet 273: 17-19.
36. Bhadricha H, Khatkhatay MI, Desai M (2019) Development of an in-house ELISA for human intact osteocalcin and its utility in diagnosis and management of osteoporosis. Clin Chim Acta 489: 117-123.
37. Hatkar S, Kadam S, Khatkhatay MI, Desai MP (2019) Screening and assessment of bone health in Indian women using an indigenous ELISA of human osteocalcin a bone turnover marker. Ind J Clin Chem.
38. Claudon A, Vergnaud P, Valverde C, Mayr A, Klause U, et al. (2008) New automated multiplex assay for bone turnover markers in osteoporosis. Clin Chem 54: 1554-1563.
39. Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, et al. (2011) International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med 49: 1271-1274.
40. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, et al. (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: A need for inter-national reference standards. Osteoporosis Int 22: 391-420.
41. Vasikaran SD, Chubb SP, Ebeling PR, Jenkins N, Jones GR, et al. (2014) Harmonised Australian reference intervals for serum PINP and CTX in adults. Clin Biochem Rev 35: 237-242.
42. Garnero P (2014) New developments in biological markers of bone metabolism in osteoporosis Bone 66: 46-55.
- Journal of Allergy Research (ISSN:2642-326X)
- International Journal of Medical and Clinical Imaging (ISSN:2573-1084)
- Journal of Neurosurgery Imaging and Techniques (ISSN:2473-1943)
- International Journal of Internal Medicine and Geriatrics (ISSN: 2689-7687)
- Journal of Cancer Science and Treatment (ISSN:2641-7472)
- Archive of Obstetrics Gynecology and Reproductive Medicine (ISSN:2640-2297)
- Journal of Pathology and Toxicology Research